{"id":"W2070730813","doi":"10.3816/clc.2011.n.004","title":"Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial","year":2011,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Takeda Oncology; Genentech; Eli Lilly and Company","keywords":"Medicine; Docetaxel; Lung cancer; Oncology; Randomized controlled trial; Internal medicine; Cancer; Bortezomib; Clinical trial; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001457336,0.0004517187,0.001541773,0.00008001731,0.0001059295,0.00001774278,0.0004614191,0.0005441239,0.0008168695],"category_scores_gemma":[0.0005310108,0.0004019507,0.0008013696,0.0001792285,0.0004902068,0.00001243945,0.0002639831,0.0005210218,0.000003481345],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001703634,"about_ca_system_score_gemma":0.002243032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001314432,"about_ca_topic_score_gemma":0.001008046,"domain_scores_codex":[0.9956147,0.000603265,0.001917878,0.0009217605,0.0002963996,0.0006459918],"domain_scores_gemma":[0.9977031,0.0002285925,0.0009649958,0.0005416075,0.0002467969,0.0003148595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9790399,0.001315706,0.0005016045,0.0001796556,0.0005600818,0.00001100981,0.000208086,0.00008384581,0.00857735,0.00002366334,0.001165842,0.00833325],"study_design_scores_gemma":[0.9293767,0.002891312,0.00001398634,0.0001818976,0.0007470642,5.393046e-7,0.00002862786,0.002158534,0.05916706,0.00001025515,0.004932637,0.0004913578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972694,0.01153115,0.0003828057,0.00009241253,0.007963319,0.005183146,0.00102383,0.00002458548,0.001104738],"genre_scores_gemma":[0.9832206,0.01000223,0.0001812172,0.000232636,0.002040448,0.003636191,0.0001470598,0.0000610533,0.0004785264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05058971,"threshold_uncertainty_score":0.9998432,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0712764897375286,"score_gpt":0.4051115447035378,"score_spread":0.3338350549660092,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}